Skip to content

Sartar Therapeutics – Revolutionizing sarcoma therapy

  • Home
  • NEED
  • SOLUTION
  • TEAM
    • Katja Ivanitskiy, M.D.
    • Harri Sihto, Ph.D.
    • Olli-Pekka Pulkka, Ph.D.
    • Olli Kallioniemi, M.D., Ph.D.
    • Pekka Simula, M.Sc.
  • News

Author: ollipulkka

24Oct

Sartar was awarded a U.S. patent 16.10.2017

Posted by ollipulkkaon October 24, 2017October 24, 2017

Sartar was awarded a USA patent for use of anagrelide in cancer therapy.

24Oct

Sartar won HealthBIO pitching competition 9.10.2017

Posted by ollipulkkaon October 24, 2017November 7, 2017

Sartar Therapeutics participated to the HealthBIO pitching competition and won it.

http://turkusciencepark.com/spark-uutiset/1673/suomalaisen-life-science-alan-vienti-vahvassa-ka/

 

18Sep

BIO-Europe Berlin November 6–8, 2017

Posted by ollipulkkaon September 18, 2017October 24, 2017

Sartar will participate in the Next Generation tract company presentations in the BIO-Europe conference at Wednesday 8th of November.

https://ebdgroup.knect365.com/bioeurope/

 

31Aug

HealthBIO Seminar and Partnering Event in Turku 5-6.9.2017

Posted by ollipulkkaon August 31, 2017October 24, 2017

Sartar participates in HealthBIO partnering event.

http://www.healthbio.fi/

22Jun

Sartar was chosen to SPARK Finland program starting at 2.5.2017

Posted by ollipulkkaon June 22, 2017October 24, 2017

SPARK Finland program is designed to increase the maturity of academic and clinical discoveries towards practical solutions in the life science and health tech space.

http://sparkfinland.fi/

Posts navigation

Previous 1 2 3 4 5 Next

Contact

Sartar Therapeutics Ltd.
c/o Terkko Health Hub
Haartmaninkatu 4, building 14
FI-00290 Helsinki
Finland
info@sartartherapeutics.com

Y-tunnus: 2754654-8
Terkko Health Hub

Search

Create a website or blog at WordPress.com
Cancel